<span id="cston"><pre id="cston"></pre></span>

        <s id="cston"><object id="cston"></object></s>
          <s id="cston"><object id="cston"><blockquote id="cston"></blockquote></object></s>
        1. <rp id="cston"></rp>
        2. GEMPHARMATECH USA

          Company Overview

          GemPharmatech is a leading contract research organization that provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. Our company is steadfast in its commitment to providing cutting-edge and novel solutions to researchers in their pursuit of scientific exploration and pharmaceutical development. At GemPharmatech, we specialize in the development of animal models utilizing advanced gene-editing technologies, and we have an extensive library of KO/cKO mice, humanized mice, immunodeficient mice, and germ-free mice. We offer a wide range of preclinical services, including mouse model customization, pharmacology services such as drug efficacy evaluation and mouse phenotyping, gene editing, cryopreservation, and customized breeding.

          Our ultimate goal is to accelerate scientific advancement and pharmaceutical development by supporting our clients with the most innovative tools and services. We have amassed one of the broadest collections of mouse models in the world, which have garnered immense popularity among scientists globally. By partnering with GemPharmatech, our clients benefit from having access to a comprehensive range of research tools and services to aid them in their research endeavors and promote scientific discovery. GemPharmatech is committed to pushing the boundaries of preclinical research and assisting our customers in achieving their research ambitions. We take great pride in providing exceptional customer service and are dedicated to providing our clients with the highest-quality research solutions.

          Genetically Engineered Mouse Models Driving Innovation

          Get Started

          Our History

          • 2017
          • 2018
          • 2019
          • 2020
          • 2021
          • 2022
          • 2023

          Leadership Team

          • Xiang Gao

            President of GemPharmatech Co. Ltd.

            Dr. Xiang Gao, an esteemed individual, has been recognized as a recipient of the prestigious National Distinguished Young Scientists Fund and appointed as a specially-appointed professor under the esteemed Chang Jiang Scholars Program by the Ministry of Education. Currently, Dr. Gao holds the position of Director at the National Genetic Engineering Mouse Resource Center, where he oversees its operations and activities. With over two decades of experience in the field, Dr. Gao has excelled in the creation and analysis of model animals. His exceptional leadership skills were demonstrated through the successfully obtained approval from the Ministry of Science and Technology for the renowned "National Genetic Engineering Mouse Resource Center" project under the National Key R&D Program of China. Further affirming his contributions, Dr. Gao's team was honored with the Second Prize of the National Science and Technology Progress Award for their remarkable work on the project "Development and Application of Gene Engineering Mouse Models for Related Diseases." Additionally, Dr. Gao's dedication to advancing scientific knowledge is evident in his extensive publication record, which includes over 130 research papers published in prestigious SCI journals.
          • Brandy Wilkinson, PhD

            Chief Executive Officer

            Brandy Wilkinson has more than 15 years of experience directing large-scale contract vivarium and research operations. Most recently, she served as a SVP of Scientific Solutions leading the ground up build of Innovive+, a scientific services division at Innovive. Previously, she was VP of Research and Operations at Explora BioLabs (acquired by Charles River Labs in 2022). Her responsibilities at Explora included management of 19 AAALAC-accredited multi-client vivaria and 50+ client owned vivaria across four key biohub cities. In addition, she has held various management and scientific roles with several preclinical oncology CROs including Covance (now LabCorp Drug Development), Champions Oncology and The Jackson Laboratory. She received her PhD in Neuroscience from Florida State University and completed her postdoctoral training at Case Western Reserve University.?
          • Lawrence Chongbo Xu, CPA, MBA

            Chief Financial Officer

            Lawrence is a certified public accountant and has over 13 years of experience in public accounting serving large U.S. and multinational corporate clients. Prior to joining GemPharmatech, he worked for Ernst & Young, RSM, and other CPA firms in the Los Angeles area, and gained a wide range of experience in Audit, Tax, and Transaction. He received his master's degree in business administration from Mississippi College. He is also a member of the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants.
          • Tao Wang, PhD

            VP of GemPharmatech CO. Ltd. & CEO of GemPharmatech subsidiary(Guangzhou, China)

            Dr. Wang Tao is a Ph.D. graduate in Biomedical Engineering from the University of Western Australia, with a multidisciplinary background in science, engineering, and biomedical fields. He has previously served as a scientist in overseas research institutions and publicly listed companies, achieving significant research breakthroughs. Upon returning to China, he joined GenPharmatech Co., Ltd as the General Manager of its Guangdong subsidiary, leading the company's establishment, research and devd elopment, production, anoperational management. He later also took on the role of Vice President of Marketing for the group, overseeing the group's marketing team and overseas business division. Internally, he successfully established a robust marketing team, while externally, he formed an overseas team, leading to a sales revenue exceeding 500 million yuan both domestically and internationally. Under his leadership, the company achieved listing during his tenure.